- Home
- CRNX vs GH Comparison
CRNX vs GH Comparison
Compare CRNX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- GH
- Stock Information
- Founded
- CRNX 2008
- GH 2011
- Country
- CRNX United States
- GH United States
- Employees
- CRNX N/A
- GH N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- GH Medical Specialities
- Sector
- CRNX Health Care
- GH Health Care
- Exchange
- CRNX Nasdaq
- GH Nasdaq
- Market Cap
- CRNX 5.2B
- GH 4.7B
- IPO Year
- CRNX 2018
- GH 2018
- Fundamental
- Price
- CRNX $37.35
- GH $36.66
- Analyst Decision
- CRNX Strong Buy
- GH Strong Buy
- Analyst Count
- CRNX 10
- GH 14
- Target Price
- CRNX $74.40
- GH $39.93
- AVG Volume (30 Days)
- CRNX 1.0M
- GH 1.9M
- Earning Date
- CRNX 02-26-2025
- GH 02-20-2025
- Dividend Yield
- CRNX N/A
- GH N/A
- EPS Growth
- CRNX N/A
- GH N/A
- EPS
- CRNX N/A
- GH N/A
- Revenue
- CRNX $1,038,999.00
- GH $692,256,000.00
- Revenue This Year
- CRNX N/A
- GH $32.21
- Revenue Next Year
- CRNX $195.21
- GH $16.90
- P/E Ratio
- CRNX N/A
- GH N/A
- Revenue Growth
- CRNX N/A
- GH 29.20
- 52 Week Low
- CRNX $35.24
- GH $15.81
- 52 Week High
- CRNX $62.53
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- CRNX 24.86
- GH 61.33
- Support Level
- CRNX $35.51
- GH $34.80
- Resistance Level
- CRNX $53.55
- GH $39.29
- Average True Range (ATR)
- CRNX 2.36
- GH 1.92
- MACD
- CRNX -1.41
- GH 0.30
- Stochastic Oscillator
- CRNX 10.14
- GH 71.96
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.